The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same

Rheumatoid Arthritis Therapy Update: What’s Changed & What’s the Same

May 15, 2020 • By Kimberly Retzlaff

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Sentavio / shutterstock.com

Sentavio / shutterstock.com

SNOWMASS VILLAGE, COLO.—Current trends in rheumatoid arthritis (RA) therapy are the increased use of newer medication categories, such as Janus kinase (JAK) inhibitors (Jakinibs) and biologics, and the rising costs of treatment. Unchanged is the consistent use of methotrexate as an effective therapy. These topics and more were discussed at the ACR Winter Symposium during the session, Update in RA Therapy: 2020, by Michael E. Weinblatt, MD, John R. and Eileen K. Riedman Professor of Medicine, Harvard Medical School, Boston, and R. Bruce and Joan M. Mickey Distinguished Chair in Rheumatology, Brigham and Women’s Hospital, Boston.

You Might Also Like
  • 4 Rheumatoid Arthritis Therapy Principles, & New Drug Info
  • Cobra Therapy for Rheumatoid Arthritis
  • New Developments in Rheumatoid Arthritis Treatment; Personalized Therapy for Patients Ultimate Goal
Explore This Issue
May 2020

Dr. Weinblatt gives this talk every year, he said, because of the importance of the topic and the ever-changing world of therapeutics in RA. “The talk was really designed to update the audience on what’s currently being published in the field of [RA] and highlight some concepts that have been emphasized over the past couple of years.”

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Topics of discussion included methotrexate, biologics, Jakinibs and issues in RA therapy, such as biosimilars and medication costs.

Methotrexate

Methotrexate remains the cornerstone of RA treatment, Dr. Weinblatt said, noting it’s currently the most common drug used to treat RA worldwide. The reason? It’s effective as a monotherapy and enhances other drugs’ efficacy when used in combination therapy. Also, one-third of patients who take it go into remission, and it’s relatively inexpensive.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dosing is a key part of any discussion of methotrexate, because it’s effective when given at a therapeutic dose of 17.5–25 mg/week, Dr. Weinblatt said. However, a June 2017 publication in Arthritis Care & Research showed that of 35,640 patients who started methotrexate, only 37% were on doses higher than 15 mg/week before they were switched to a biologic.1

“Rheumatologists should dose escalate with methotrexate, and only after achieving doses of 20–25 milligrams per week should you think about adding another drug,” Dr. Weinblatt recommended. At these doses, because the bioavailability may be reduced, the drug should be administered either as a weekly subcutaneous injection or in two doses, once in the morning and once in the evening, once a week.

This modified regimen may also help address intolerance related to gastro­intestinal distress, nausea and fatigue, which are the most common reasons patients stop taking methotrexate. Other options to minimize toxicities, said Dr. Weinblatt, are to lower the dose or to take supplements, such as folic acid or—if that fails—folinic acid at least eight hours after the methotrexate.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Rheumatoid Arthritis Tagged With: costs, janus kinase inhibitor, Methotrexate, RA Resource Center, Winter Rheumatology SummitIssue: May 2020

You Might Also Like:
  • 4 Rheumatoid Arthritis Therapy Principles, & New Drug Info
  • Cobra Therapy for Rheumatoid Arthritis
  • New Developments in Rheumatoid Arthritis Treatment; Personalized Therapy for Patients Ultimate Goal
  • ACR 2013 State-of-the-Art Clinical Symposium: What’s Next in Therapy for Osteoarthritis, Rheumatoid Arthritis, and Lupus?

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)